Intellia Therapeutics Announces Second Quarter 2019 Financial Results and Company Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall St rebounds with broad gains as oil slides sharply
- Brent hits lowest since before start of Iran war as more tankers exit Hormuz, easing supply
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Intellia Therapeutics (NTLA) Tops Q2 EPS by 4c, Revenues Beat
August 1, 2019 7:45 AM EDTIntellia Therapeutics (NASDAQ: NTLA) reported Q2 EPS of ($0.56), $0.04 better than the analyst estimate of ($0.60). Revenue for the quarter came in at $11.11 million versus the consensus estimate of $7.11 million.
We continue to build our in vivo and engineered cell therapy pipeline in support of... More
